AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?
This article was originally published in The Pink Sheet Daily
Executive Summary
With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.